Cabozantinib: An evolving therapy for hepatocellular carcinoma
Clicks: 272
ID: 267326
2021
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.3
/100
272 views
37 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #1 of 5 articles by views in Cancer treatment reviews
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Hepatocellular carcinoma (HCC) is rising in incidence and remains a leading cause of cancer-related death. After a decade of disappointing trials following the approval of sorafenib for patients with advanced HCC, a number of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies targeting angi …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (43 words).
Try re-searching for a better abstract.
| Reference Key |
ab2021cancercabozantinib:
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | El-Khoueiry AB;Hanna DL;Llovet J;Kelley RK;; |
| Journal | Cancer treatment reviews |
| Year | 2021 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
animals
humans
pubmed abstract
nih
national institutes of health
national library of medicine
carcinoma
hepatocellular / pathology
liver neoplasms / pathology
liver neoplasms / drug therapy*
hepatocellular / drug therapy*
pmid:34029957
doi:10.1016/j.ctrv.2021.102221
anthony b el-khoueiry
diana l hanna
robin kate kelley
anilides / therapeutic use*
antineoplastic agents / therapeutic use*
pyridines / therapeutic use*
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.